SYNGENE INTER increases its risk exposure and slightly lowers to Neutral
SYNGENE INTER (IN), a company active in the Biotechnology industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date February 18, 2022, the closing price was INR 563.50 and its expected value was estimated at INR 587.79.Syngene International Limited is a contract research company. The Company is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies. Its services include discovery chemistry and biology services, toxicology, pharmaceutical development, process development/manufacture of intermediates, active pharmaceutical ingredients and bio-therapeutics. Its services encompass integrated, discovery and development services for novel molecular entities (NMEs) across industrial sectors, including pharmaceutical, biopharmaceutical and biotechnology, among others. It specializes in conducting discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, and stability studies) and manufacturing (scale-up, pre-clinical and manufacturing supplies). It serves clients ranging from multinational corporations to start-ups.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.